Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

This result is comparable to Eli Lilly's Phase 3 SURMOUNT-1 trial of tirzepatide, which showed up to a 22.5% weight loss at the same time point. Although Novo Nordisk has not released detailed ...

Salesforce has given $1 million to College Possible, the national nonprofit promoting college access by students from ...

Image: Adobe Stock SURMOUNT-OSA consisted of two phase 3 trials in which adults with obesity and moderate or severe OSA were randomly assigned to once-weekly tirzepatide or placebo for 1 year.

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Leerink Partners maintained a positive outlook on shares of Eli Lilly and Company (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $950.00. The pharmaceutical giant, currently ...

President John Dramani Mahama Friday swore in five more Ministers at the Flag Staff House, following parliamentary approval, bringing to 11 the total number of ministers in office so far.The five ...

Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity treatment market, according to a ...

announced today positive topline results from the SURMOUNT-1 three-year study (176-week treatment period) evaluating the efficacy and safety of... INDIANAPOLIS - Eli Lilly and Company (NYSE ...

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024 Jan 2;331(1):38-48. doi: 10.1001/jama.

The Lobos’ home arena, aptly named The Pit, is considered one of the tougher arenas to visit in the Mountain West — last week ...